CN106619676A - 一种用于缓解牙痛的止痛药 - Google Patents
一种用于缓解牙痛的止痛药 Download PDFInfo
- Publication number
- CN106619676A CN106619676A CN201611011438.5A CN201611011438A CN106619676A CN 106619676 A CN106619676 A CN 106619676A CN 201611011438 A CN201611011438 A CN 201611011438A CN 106619676 A CN106619676 A CN 106619676A
- Authority
- CN
- China
- Prior art keywords
- parts
- toothache
- analgesic
- glucurolactone
- carrageenan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000004371 toothache Diseases 0.000 title claims abstract description 50
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims abstract description 35
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims abstract description 28
- SKKNACBBJGLYJD-UHFFFAOYSA-N bismuth magnesium Chemical compound [Mg].[Bi] SKKNACBBJGLYJD-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000001509 sodium citrate Substances 0.000 claims abstract description 19
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 19
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 claims abstract description 18
- 239000000679 carrageenan Substances 0.000 claims abstract description 18
- 229940113118 carrageenan Drugs 0.000 claims abstract description 18
- 235000010418 carrageenan Nutrition 0.000 claims abstract description 18
- 229920001525 carrageenan Polymers 0.000 claims abstract description 18
- 229950002441 glucurolactone Drugs 0.000 claims abstract description 18
- 229960000905 indomethacin Drugs 0.000 claims abstract description 18
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims abstract description 18
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960004420 aceclofenac Drugs 0.000 claims abstract description 14
- 229960001603 tamoxifen Drugs 0.000 claims abstract description 14
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 13
- 208000002193 Pain Diseases 0.000 claims abstract description 7
- 230000036407 pain Effects 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 4
- 230000000202 analgesic effect Effects 0.000 claims description 34
- IAWWAVGUKRSONG-UHFFFAOYSA-N 2,4-dimethyl-2-phenylpentanoic acid Chemical compound CC(C)CC(C)(C(O)=O)C1=CC=CC=C1 IAWWAVGUKRSONG-UHFFFAOYSA-N 0.000 claims description 17
- 241001505096 Rhamnus davurica Species 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- -1 isobutylphenyl Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229910021642 ultra pure water Inorganic materials 0.000 claims 1
- 239000012498 ultrapure water Substances 0.000 claims 1
- 208000002925 dental caries Diseases 0.000 abstract description 4
- 201000001245 periodontitis Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 241000219100 Rhamnaceae Species 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 210000000515 tooth Anatomy 0.000 description 25
- 239000002253 acid Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- PDNNQADNLPRFPG-UHFFFAOYSA-N N.[O] Chemical compound N.[O] PDNNQADNLPRFPG-UHFFFAOYSA-N 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 235000021419 vinegar Nutrition 0.000 description 5
- 239000000052 vinegar Substances 0.000 description 5
- 210000004268 dentin Anatomy 0.000 description 4
- 210000003298 dental enamel Anatomy 0.000 description 3
- 210000003074 dental pulp Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000006558 Dental Calculus Diseases 0.000 description 2
- 201000004328 Pulpitis Diseases 0.000 description 2
- 206010037464 Pulpitis dental Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004489 deciduous teeth Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000004195 gingiva Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012946 outsourcing Methods 0.000 description 1
- 208000004480 periapical periodontitis Diseases 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000001114 tooth apex Anatomy 0.000 description 1
- 210000004746 tooth root Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种用于缓解牙痛的止痛药，所述用于缓解牙痛的止痛药，按照重量份的主要原料为：对异丁苯基丙酸13‑18份、醋氯芬酸2‑6份、阿司匹林10‑20份、吲哚美辛13‑15份、葡醛内酯4‑9份、卡拉胶2‑6份、鼠李铋镁0.2‑0.7份、三苯氧氨5‑8份、枸橼酸钠2‑8份。本发明主要医治蛀牙痛、风火牙痛、牙周炎、神经性牙痛、细菌性感染牙痛等病，使用时，只要将本成品药涂敷于患病处，在3‑5秒钟内解除牙痛，达到理想治疗效果。
Description
技术领域
本发明涉及一种医药制备领域，具体是一种用于缓解牙痛的止痛药。
背景技术
牙齿是一种在很多脊椎动物上存在的结构，牙齿是人类身体最坚硬的器官。人的一生有两副天然牙，一副是乳牙，一副是恒牙。乳牙掉了后，便长出了恒牙。恒牙掉后不能再生。随着社会科技的进步与发展，义齿成为人类的第三副牙。人们在日常生活中，通过牙齿的配合进行发声说话、咀嚼饮食等行为。同时，牙齿的健康、美观也与咱们的日常各方面紧密相关。每个牙都分为牙冠、牙根和牙颈三部分。牙冠是露出于口腔的部分，洁白而有光泽；牙根嵌于牙槽内，借牙周膜与骨质结合，牙根尖部有一孔，称为牙根尖孔，有血管、神经出入，牙颈为牙冠和牙根间稍细的部分，外包以牙龈。牙的构造主要是由牙质构成，在牙根部牙质的外面包有一层粘合质(牙骨质)，而在牙冠部表面有白色、光亮、坚硬的釉质。釉质是人体中钙化程度最高的组织。牙内部的腔隙称为牙腔，牙腔内充满血管、神经和结缔组织，称为牙髓。口腔内的乳酸杆菌能使糖类酵解产酸，导致釉质脱钙，产生空洞，临床称为龋齿。若龋洞不断加深，波及牙髓的神经，则可引起剧痛。牙痛是指牙齿因各种原因引起的疼痛，为口腔疾患中常见的症状之一，可见于龋齿、牙髓炎、根尖周炎、牙外伤、牙本质过敏、楔状缺损等。牙痛大多由牙龈炎和牙周炎、龋齿(蛀牙)或折裂牙而导致牙髓(牙神经)感染所引起的。是由于不注意口腔卫生，牙齿受到牙齿周围食物残渣、细菌等物结成的软质的牙垢和硬质的牙石所致的长期刺激，及不正确的刷牙习惯，维生素缺乏等原因所造成。
因此，急需研发一种适合疗效好、速度快、价格低、无毒副作用的止痛药。
发明内容
本发明的目的在于提供一种用于缓解牙痛的止痛药，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：
一种用于缓解牙痛的止痛药，按照重量份的主要原料为：对异丁苯基丙酸13-18份、醋氯芬酸2-6份、阿司匹林10-20份、吲哚美辛13-15份、葡醛内酯4-9份、卡拉胶2-6份、鼠李铋镁0.2-0.7份、三苯氧氨5-8份、枸橼酸钠2-8份。
作为本发明进一步的方案：所述用于缓解牙痛的止痛药，按照重量份的主要原料为：对异丁苯基丙酸14-16份、醋氯芬酸3-5份、阿司匹林13-18份、吲哚美辛13-15份、葡醛内酯5-8份、卡拉胶2-6份、鼠李铋镁0.4-0.6份、三苯氧氨5-8份、枸橼酸钠3-6份。
作为本发明进一步的方案：所述用于缓解牙痛的止痛药，按照重量份的主要原料为：对异丁苯基丙酸15份、醋氯芬酸4份、阿司匹林16份、吲哚美辛14份、葡醛内酯7份、卡拉胶4份、鼠李铋镁0.5份、三苯氧氨7份、枸橼酸钠5份。
一种用于缓解牙痛的止痛药的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取对异丁苯基丙酸、醋氯芬酸、阿司匹林、吲哚美辛、葡醛内酯、卡拉胶、鼠李铋镁、三苯氧氨、枸橼酸钠，过筛，机械混匀后添加超纯水，放置制药混合机中，混合4-8min，控制RSD≤5％，混合后压片并低温干燥，温度控制在4-8℃，包装即得用于缓解牙痛的止痛药。
作为本发明进一步的方案：具体步骤中混合6min。
作为本发明进一步的方案：具体步骤中温度控制在6℃。
与现有技术相比，本发明的有益效果是：
本发明主要医治蛀牙痛、风火牙痛、牙周炎、神经性牙痛、细菌性感染牙痛等病，使用时，只要将本成品药涂敷于患病处，在3-5秒钟内解除牙痛，达到理想治疗效果。
具体实施方式
下面将结合本发明实施例，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1
一种用于缓解牙痛的止痛药，按照重量份的主要原料为：对异丁苯基丙酸13份、醋氯芬酸2份、阿司匹林10份、吲哚美辛13份、葡醛内酯4份、卡拉胶2份、鼠李铋镁0.2份、三苯氧氨5份、枸橼酸钠2份。
一种用于缓解牙痛的止痛药的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取对异丁苯基丙酸、醋氯芬酸、阿司匹林、吲哚美辛、葡醛内酯、卡拉胶、鼠李铋镁、三苯氧氨、枸橼酸钠，过筛，机械混匀后添加超纯水，放置制药混合机中，混合4min，控制RSD≤5％，混合后压片并低温干燥，温度控制在4℃，包装即得用于缓解牙痛的止痛药。
实施例2
一种用于缓解牙痛的止痛药，按照重量份的主要原料为：对异丁苯基丙酸14份、醋氯芬酸3份、阿司匹林13份、吲哚美辛13份、葡醛内酯5份、卡拉胶2份、鼠李铋镁0.4份、三苯氧氨5份、枸橼酸钠3份。
一种用于缓解牙痛的止痛药的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取对异丁苯基丙酸、醋氯芬酸、阿司匹林、吲哚美辛、葡醛内酯、卡拉胶、鼠李铋镁、三苯氧氨、枸橼酸钠，过筛，机械混匀后添加超纯水，放置制药混合机中，混合4min，控制RSD≤5％，混合后压片并低温干燥，温度控制在4℃，包装即得用于缓解牙痛的止痛药。
实施例3
一种用于缓解牙痛的止痛药，按照重量份的主要原料为：对异丁苯基丙酸15份、醋氯芬酸4份、阿司匹林16份、吲哚美辛14份、葡醛内酯7份、卡拉胶4份、鼠李铋镁0.5份、三苯氧氨7份、枸橼酸钠5份。
一种用于缓解牙痛的止痛药的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取对异丁苯基丙酸、醋氯芬酸、阿司匹林、吲哚美辛、葡醛内酯、卡拉胶、鼠李铋镁、三苯氧氨、枸橼酸钠，过筛，机械混匀后添加超纯水，放置制药混合机中，混合6min，控制RSD≤5％，混合后压片并低温干燥，温度控制在6℃，包装即得用于缓解牙痛的止痛药。
实施例4
一种用于缓解牙痛的止痛药，按照重量份的主要原料为：对异丁苯基丙酸16份、醋氯芬酸5份、阿司匹林18份、吲哚美辛15份、葡醛内酯8份、卡拉胶6份、鼠李铋镁0.6份、三苯氧氨8份、枸橼酸钠6份。
一种用于缓解牙痛的止痛药的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取对异丁苯基丙酸、醋氯芬酸、阿司匹林、吲哚美辛、葡醛内酯、卡拉胶、鼠李铋镁、三苯氧氨、枸橼酸钠，过筛，机械混匀后添加超纯水，放置制药混合机中，混合8min，控制RSD≤5％，混合后压片并低温干燥，温度控制在8℃，包装即得用于缓解牙痛的止痛药。
实施例5
一种用于缓解牙痛的止痛药，按照重量份的主要原料为：对异丁苯基丙酸18份、醋氯芬酸6份、阿司匹林20份、吲哚美辛15份、葡醛内酯9份、卡拉胶6份、鼠李铋镁0.7份、三苯氧氨8份、枸橼酸钠8份。
一种用于缓解牙痛的止痛药的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取对异丁苯基丙酸、醋氯芬酸、阿司匹林、吲哚美辛、葡醛内酯、卡拉胶、鼠李铋镁、三苯氧氨、枸橼酸钠，过筛，机械混匀后添加超纯水，放置制药混合机中，混合8min，控制RSD≤5％，混合后压片并低温干燥，温度控制在8℃，包装即得用于缓解牙痛的止痛药。
临床试验
1、病例来源
在四川大学华西口腔医院门诊部筛选300例牙痛志愿患者，男150例，女150例，年龄12～65岁，平均年龄40.7岁，火牙患者213例，龋齿患者204例，牙周炎75例，牙髓炎56例，牙本质过敏82例，牙疼表现为：持续性或间歇性疼痛、牙龈红肿、部分有出血现象，患者牙痛时间最短一天，最长17天，平均7.4天。将所有患者平均分为5组，各组患者无统计学差异。
2、治疗方法上述5组患者分别按照本发明的方法服用上述实施例3制备的止痛药，3日为一疗程，每天2次，每次1g，观察一疗程后治疗结果。
3、疗效标准显效：牙齿疼痛、红肿出血等临床症状全部消失；有效：牙痛发作次数以及发作时疼痛的程度比治疗前明显减轻。无效：治疗前后症状无明显变化或加重。
4、结果：实施例3制备的止痛药，显效总人数为287例，有效人数为8例，无效人数为5例，总有效率为98.3％。
对于本领域技术人员而言，显然本发明不限于上述示范性实施例的细节，而且在不背离本发明的精神或基本特征的情况下，能够以其他的具体形式实现本发明。因此，无论从哪一点来看，均应将实施例看作是示范性的，而且是非限制性的，本发明的范围由所附权利要求而不是上述说明限定，因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外，应当理解，虽然本说明书按照实施方式加以描述，但并非每个实施方式仅包含一个独立的技术方案，说明书的这种叙述方式仅仅是为清楚起见，本领域技术人员应当将说明书作为一个整体，各实施例中的技术方案也可以经适当组合，形成本领域技术人员可以理解的其他实施方式。
Claims (6)
1.一种用于缓解牙痛的止痛药，其特征在于，按照重量份的主要原料为：对异丁苯基丙酸13-18份、醋氯芬酸2-6份、阿司匹林10-20份、吲哚美辛13-15份、葡醛内酯4-9份、卡拉胶2-6份、鼠李铋镁0.2-0.7份、三苯氧氨5-8份、枸橼酸钠2-8份。
2.根据权利要求1所述的用于缓解牙痛的止痛药，其特征在于，所述用于缓解牙痛的止痛药，按照重量份的主要原料为：对异丁苯基丙酸14-16份、醋氯芬酸3-5份、阿司匹林13-18份、吲哚美辛13-15份、葡醛内酯5-8份、卡拉胶2-6份、鼠李铋镁0.4-0.6份、三苯氧氨5-8份、枸橼酸钠3-6份。
3.根据权利要求1或2所述的用于缓解牙痛的止痛药，其特征在于，所述用于缓解牙痛的止痛药，按照重量份的主要原料为：对异丁苯基丙酸15份、醋氯芬酸4份、阿司匹林16份、吲哚美辛14份、葡醛内酯7份、卡拉胶4份、鼠李铋镁0.5份、三苯氧氨7份、枸橼酸钠5份。
4.一种如权利要求1-3任一所述的用于缓解牙痛的止痛药的制备方法，其特征在于，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取对异丁苯基丙酸、醋氯芬酸、阿司匹林、吲哚美辛、葡醛内酯、卡拉胶、鼠李铋镁、三苯氧氨、枸橼酸钠，过筛，机械混匀后添加超纯水，放置制药混合机中，混合4-8min，控制RSD≤5％，混合后压片并低温干燥，温度控制在4-8℃，包装即得用于缓解牙痛的止痛药。
5.根据权利要求4所述的用于缓解牙痛的止痛药的制备方法，其特征在于，具体步骤中混合6min。
6.根据权利要求4所述的用于缓解牙痛的止痛药的制备方法，其特征在于，具体步骤中温度控制在6℃。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611011438.5A CN106619676A (zh) | 2016-11-17 | 2016-11-17 | 一种用于缓解牙痛的止痛药 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611011438.5A CN106619676A (zh) | 2016-11-17 | 2016-11-17 | 一种用于缓解牙痛的止痛药 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106619676A true CN106619676A (zh) | 2017-05-10 |
Family
ID=58808021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611011438.5A Pending CN106619676A (zh) | 2016-11-17 | 2016-11-17 | 一种用于缓解牙痛的止痛药 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106619676A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108553471A (zh) * | 2018-04-29 | 2018-09-21 | 广东伊茗药业有限公司 | 一种盐酸他喷他多塞来昔布制剂 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101305969A (zh) * | 2008-07-08 | 2008-11-19 | 美国Okoic公司 | 一种口腔消毒卫生用品 |
| WO2007103540A3 (en) * | 2006-03-08 | 2008-12-18 | Pharmena North America Inc | Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries |
| CN101627986A (zh) * | 2009-08-14 | 2010-01-20 | 海南永田药物研究院有限公司 | 醋氯芬酸对乙酰氨基酚药物组合物及其脂质体固体制剂 |
-
2016
- 2016-11-17 CN CN201611011438.5A patent/CN106619676A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007103540A3 (en) * | 2006-03-08 | 2008-12-18 | Pharmena North America Inc | Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries |
| CN101305969A (zh) * | 2008-07-08 | 2008-11-19 | 美国Okoic公司 | 一种口腔消毒卫生用品 |
| CN101627986A (zh) * | 2009-08-14 | 2010-01-20 | 海南永田药物研究院有限公司 | 醋氯芬酸对乙酰氨基酚药物组合物及其脂质体固体制剂 |
Non-Patent Citations (1)
| Title |
|---|
| 刘松青 主编: "《实用药物手册》", 31 October 2007, 四川大学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108553471A (zh) * | 2018-04-29 | 2018-09-21 | 广东伊茗药业有限公司 | 一种盐酸他喷他多塞来昔布制剂 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Amato et al. | Bleaching teeth treated endodontically: long-term evaluation of a case series | |
| Shah | Paediatric dentistry-novel evolvement | |
| CN106619676A (zh) | 一种用于缓解牙痛的止痛药 | |
| CN106309740A (zh) | 一种清洁口腔的药物 | |
| Symons et al. | Pulpal obliteration related to long‐term glucocorticosteroid medication | |
| Ottofy | Standard dental dictionary | |
| RU2356530C1 (ru) | Средство для полоскания полости рта при протезном стоматите и парадонтите | |
| CN106619761A (zh) | 一种缓解牙痛的止痛药 | |
| CN101185695B (zh) | 治疗牙痛的中药外涂药 | |
| Ashok et al. | Geriatric Oral health care | |
| Goncharuk-Khomyn et al. | Educational and methodological recommendations for 2nd-year students in the discipline «Propaedeutics of Therapeutic dentistry». | |
| Gopikrishna | Sturdevant's Art & Science of Operative Dentistry-E Book: Second South Asia Edition | |
| RU2204991C1 (ru) | Состав для профилактики заболеваний полости рта | |
| RU2542469C1 (ru) | Средство для местной терапии рецидивирующих афт полости рта при стоматите зубных рядов и пародонтите | |
| Skikevych et al. | The basics of stomatology | |
| Horzov et al. | Periodontology | |
| Kozachenko et al. | Basic Dentistry | |
| Verma et al. | AESTHETIC REHABILITATION WITH PORCELAIN VENEERS FOR SPACED ANTERIOR TEETH. | |
| Cao et al. | Oral-Lung Connection: Prevotella Intermedia Identified In Lung Abscess | |
| Ungureanu et al. | Prevention in dental medicine: case studies and explanations regarding the cost-benefit ratio | |
| Altira | (Elham Altira) Comprehensive case management-Full mouth rehabilitation | |
| Grove | A new departure in root-canal practice | |
| Handoko | The 1st Bali International Dental Symposium | |
| Mendoza | Oral Health A Study Guide for Medical Students & Physicians | |
| Furnadzhieva et al. | Oral cavity changes during and aftercancer therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170510 |